Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 5/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 3/20 | 0.32 |
| ▸ | CASP7 | P55210 | 3/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | USP1 | O94782 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327481 | 0.88 | HTR2C (0.34) | ALDH1A1HTTPOLBHTR2CMTNR1A | |
| SCHEMBL910261 | 0.81 | CYP2C19 (0.33) | ALDH1A1HTTPOLB | |
| SCHEMBL910245 | 0.77 | BRD4 (0.34) | ALDH1A1HTTPOLBHTR2CMTNR1A | |
| SCHEMBL909767 | 0.76 | CYP2D6 (0.33) | HTR2CMTNR1AMTNR1BRIPK1HTR1A | |
| SCHEMBL910104 | 0.75 | GPR84 (0.35) | ALDH1A1HTTHTR2CMTNR1AMTNR1B | |
| SCHEMBL335895 | 0.72 | HTR2C (0.36) | HTR2CMTNR1AMTNR1BRIPK1HTR2A | |
| SCHEMBL3332876 | 0.72 | HTR2C (0.36) | HTR2CMTNR1AMTNR1BRIPK1HTR2A | |
| SCHEMBL335894 | 0.72 | HTR2C (0.36) | HTR2CMTNR1AMTNR1BRIPK1HTR2A | |
| SCHEMBL3328929 | 0.71 | CHRM1 (0.42) | HTR2CMTNR1AMTNR1BRIPK1 | |
| SCHEMBL3333076 | 0.71 | CHRM1 (0.42) | HTR2CMTNR1AMTNR1BRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| EP-2238138-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009087153-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NRDC, NCL, NPM1 | ALDH1A1 4501/4885HTT 1223/4885POLB 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.